bioAffinity Technologies
Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.
Something off on this page? Send us feedback.
Profile
Provides clinical pathology services and CyPath Lung, a sputum-based laboratory-developed test that helps physicians assess high-risk patients with suspicious lung nodules. Nearly all revenue flows through the San Antonio laboratory, the sole commercial provider of CyPath Lung.
Combines Precision Pathology Laboratory Services, a San Antonio clinical-pathology laboratory, with CyPath Lung, a sputum-based test using flow cytometry and automated analysis to aid physicians evaluating high-risk adults with small or indeterminate pulmonary nodules. The laboratory also supplies anatomic and clinical pathology services, with samples sent overnight from across the United States to its sole processing site.
Generates nearly all revenue through laboratory services, including patient, histology, and medical-director fees, while its diagnostic R&D segment supports observational studies and research-stage asthma/COPD diagnostics. CyPath Lung is offered as an LDT through the CAP-accredited, CLIA-certified laboratory rather than under FDA marketing authorization; reimbursement, state permissions, courier logistics, and the San Antonio facility are core operating dependencies.
Company facts
Key statistics
Year to date −73.4% · Average volume (30d) 425.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$2.10 | −$0.64 | +69.5% | $1.7M | $1.5M | −11.2% | −3.77% |
| May 8, 2026Q1 FY26 | −$2.40 | −$0.81 | +66.3% | $1.5M | $1.4M | −8.9% | −2.96% |
| Mar 13, 2026Q4 FY25 | −$2.70 | −$1.11 | +58.9% | $1.6M | $1.6M | +2.5% | −9.91% |
| Nov 14, 2025Q3 FY25 | −$2.70 | −$2.70 | 0.0% | $1.4M | $1.4M | +2.5% | −14.13% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.3M | $1.4M | $1.6M | $1.4M | $1.5M | |
| Gross profit | $485.7K | $252.9K | $390.5K | $301.2K | $308.4K | −$3.3M | |
| Operating income | −$2.6M | −$2.5M | −$2.3M | −$3.1M | −$3.6M | −$3.3M | |
| Net income | −$2.7M | −$4.1M | −$5.1M | −$3.1M | −$3.6M | −$3.4M | |
| Diluted EPS | −$4.80 | −$5.07 | −$4.74 | −$1.82 | −$12.15 | −$9.60 | |
| Gross margin | 26.2% | 19.9% | 27.0% | 18.9% | 22.8% | -220.8% | |
| Operating margin | -141.7% | -198.2% | -158.6% | -196.9% | -267.6% | -220.8% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $4.8K · FY23 $2.5M · FY24 $9.4M · FY25 $6.2M
Revenue by product · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $2.4M · Total debt $1.4M · Total assets $7.6M · Shareholders' equity $3.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 418.9K · Float 294.8K · 70.4% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Biodesix
Blood-based lung-nodule tests contest the same diagnostic decision.
- Veracyte
A nasal genomic test targets the same indeterminate lung nodules.
- Quest Diagnostics
National laboratory and hospital-management services overlap with PPLS.
- Labcorp
National anatomic-pathology capacity contests PPLS laboratory services.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| bioAffinity Technologies | $4.90 | +0.62% | $2.0M | — | — | 0.3 | +19.0% |
| Biodesix | $26.83 | +0.22% | $218.4M | — | — | 2.1 | +34.2% |
| Veracyte | $44.20 | +2.01% | $3.46B | 31.0 | 23.9 | 6.2 | +15.5% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Median | 27.7 | 21.2 | 2.2 | +12.9% |